KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Halozyme Therapeutics (HALO) Non Operating Income: 2009-2024

Historic Non Operating Income for Halozyme Therapeutics (HALO) over the last 13 years, with Dec 2024 value amounting to $23.8 million.

  • Halozyme Therapeutics' Non Operating Income fell 17.62% to $5.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $26.3 million, marking a year-over-year increase of 20.29%. This contributed to the annual value of $23.8 million for FY2024, which is 45.57% up from last year.
  • According to the latest figures from FY2024, Halozyme Therapeutics' Non Operating Income is $23.8 million, which was up 45.57% from $16.3 million recorded in FY2023.
  • Over the past 5 years, Halozyme Therapeutics' Non Operating Income peaked at $23.8 million during FY2024, and registered a low of $1.0 million during FY2022.
  • Over the past 3 years, Halozyme Therapeutics' median Non Operating Income value was $16.3 million (recorded in 2023), while the average stood at $13.7 million.
  • In the last 5 years, Halozyme Therapeutics' Non Operating Income crashed by 79.69% in 2021 and then surged by 1,459.94% in 2023.
  • Halozyme Therapeutics' Non Operating Income (Yearly) stood at $5.4 million in 2020, then slumped by 79.69% to $1.1 million in 2021, then dropped by 5.08% to $1.0 million in 2022, then soared by 1,459.94% to $16.3 million in 2023, then surged by 45.57% to $23.8 million in 2024.